Assignee
TOLERO PHARMACEUTICALS INC
US·19 granted patents·9 pending applications·189 citations·filing 2013–2020
Top patents by PatentIndex Score
28 records- 0197US9758539B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Sep 12, 2017·24 cites·13 claims
- 0296US10568887B2Combination therapies for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 25, 2020·10 cites·1 claims
- 0396US10259835B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2017·Granted Apr 16, 2019·17 cites·13 claims
- 0496US9901574B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 27, 2018·18 cites·12 claims
- 0595US10267787B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Apr 23, 2019·13 cites·13 claims
- 0695US9394257B2PKM2 modulators and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2013·Granted Jul 19, 2016·22 cites·52 claims
- 0794US10562925B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Feb 18, 2020·10 cites·20 claims
- 0894US10357488B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Jul 23, 2019·12 cites·8 claims
- 0993US10132797B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2017·Granted Nov 20, 2018·15 cites·15 claims
- 1092US10624880B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Apr 21, 2020·7 cites·16 claims
- 1192US10422788B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Sep 24, 2019·11 cites·19 claims
- 1292US10202356B2JAK2 and ALK2 inhibitors and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2014·Granted Feb 12, 2019·12 cites·10 claims
- 1391US10682356B2Combination therapies for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Jun 16, 2020·7 cites·1 claims
- 1484US10047093B2Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitorsTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Aug 14, 2018·3 cites·42 claims
- 1583US10752594B2JAK1 and ALK2 inhibitors and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Aug 25, 2020·1 cites·11 claims
- 1683US10392392B2Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitorsTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Aug 27, 2019·2 cites·35 claims
- 1782US10766865B2PKM2 modulators and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Sep 8, 2020·1 cites·17 claims
- 1882US10472328B2PKM2 modulators and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Nov 12, 2019·2 cites·20 claims
- 1979US10207996B2PKM2 modulators and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 19, 2019·2 cites·37 claims
- 2073US2020131210A1Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2172US2020200737A1Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2266US2020276174A1Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2363US2019314357A1Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2457US2020323851A1Alk5 inhibitors for treating myelodysplastic syndromeTOLERO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2555US2020316084A1Methods to target transcriptional control at super-enhancer regionsTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2653US2018280407A1Methods to target transcriptional control at super-enhancer regionsTOLERO PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2749US2020237766A1Pkm2 activators in combination with reactive oxygen species for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2849US2020281949A1Methods for treating castration-resistant and castration-sensitive prostate cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when TOLERO PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →